GLENMARK.NS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 18:00):

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally...

Stats
今日成交量	414 868
平均成交量	1.22M
市值	293.66B
EPS	INR-12.45 ( 2024-02-15 )
下一个收益日期	( INR7.93 ) 2024-05-15
Last Dividend	INR2.50 ( 2023-09-18 )
Next Dividend	INR0 ( N/A )
P/E	-38.44
ATR14	INR0.879 (0.08%)

音量相关性

長: 0.14 (neutral)

短: 0.98 (very strong)

Signal:(46.701) Expect same movement, but be aware

Glenmark Pharmaceuticals 相关性

10 最正相关
AUROPHARMA.NS	0.938
ADORWELD.NS	0.93
ANURAS.NS	0.923
IZMO.NS	0.914
GISOLUTION.NS	0.907
ANMOL.NS	0.905
CAREERP.NS	0.889
KSB.NS	0.884
SETF10GILT.NS	0.879
GTNTEX.NS	0.876

10 最负相关
KOHINOOR.NS	-0.876
SEYAIND.NS	-0.867
DEEPINDS.NS	-0.855
MERCATOR.NS	-0.849
STARTECK.NS	-0.835
ALLCARGO.NS	-0.808
ORTINLAB.NS	-0.807
KBCGLOBAL.NS	-0.803
SWANENERGY.NS	-0.803

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Glenmark Pharmaceuticals 相关性 - 货币/商品

0.32
( neutral )

0.16
( neutral )

0.28
( neutral )

0.61
( weak )

-0.16
( neutral )

0.25
( neutral )

Glenmark Pharmaceuticals 财务报表

Annual	2022
营收:	INR127.25B
毛利润:	INR81.88B (64.35 %)
EPS:	INR10.53

FY	2022
营收:	INR127.25B
毛利润:	INR81.88B (64.35 %)
EPS:	INR10.53

FY	2022
营收:	INR121.74B
毛利润:	INR77.14B (63.37 %)
EPS:	INR33.37

FY	2021
营收:	INR108.06B
毛利润:	INR70.62B (65.35 %)
EPS:	INR34.38

Financial Reports:

No articles found.

Glenmark Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR2.50 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR2.50 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Glenmark Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 0.0208 - low (50.00%) | Divividend Growth Potential Score: 2.80 - Decrease likely (44.09%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.600	2002-09-12
Last Dividend	INR2.50	2023-09-18
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	22	--
Total Paid Out	INR30.90	--
Avg. Dividend % Per Year	0.37%	--
Score	1.29	--
Div. Sustainability Score	0.0208
Div.Growth Potential Score	2.80
Div. Directional Score	1.408	--

Next Divdend (Est)
(2024-07-01)

INR2.59 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.29

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.38%
2019	INR2.00	0.29%
2020	INR2.50	0.72%
2021	INR2.50	0.50%
2022	INR2.50	0.48%
2023	INR2.50	0.59%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
PTC.NS	Dividend Knight	2023-09-20	Annually	21	6.06%
KDDL.NS	Dividend Junior	2023-09-22	Annually	8	0.29%
ELDEHSG.NS	Dividend Junior	2023-09-15	Annually	3	0.63%
AHLADA.NS	Dividend Junior	2023-09-22	Annually	6	0.95%
SUNDARMHLD.NS	Dividend Junior	2023-07-03	Annually	7	1.35%
NATIONALUM.NS	Dividend Knight	2023-09-15	Semi-Annually	26	4.12%
HLEGLAS.NS	Dividend Junior	2023-09-21	Annually	4	0.19%
CANTABIL.NS	Dividend Junior	2023-09-15	Annually	5	0.63%
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0581	1.500	-1.161	-1.742	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0742	1.500	-1.935	-2.90	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.901	1.000	-0.407	-0.407	[3 - 30]
operatingCashFlowPerShareTTM	31.65	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	31.65	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.0740	1.000	-0.520	-0.520	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				0.0208

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-41.43	1.000	-4.29	0	[1 - 100]
returnOnEquityTTM	-0.0742	2.50	-1.244	-2.90	[0.1 - 1.5]
freeCashFlowPerShareTTM	31.65	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.239	1.500	4.02	0	[0 - 0.4]
operatingCashFlowPerShareTTM	31.65	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.605	1.500	9.30	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0729	1.000	-0.678	0	[0.1 - 0.5]
Total Score				2.80

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.